Cargando…

BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors

BACKGROUND: We tested the hypothesis that inhibitor of apoptosis family (IAP) proteins may be altered in BRCA1-mutated ovarian cancers and that could affect the sensitivity to IAP inhibitors. METHODS: The levels of IAP proteins were evaluated in human cancers and cell lines. Cell lines were used to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cremona, Mattia, Vandenberg, Cassandra J., Farrelly, Angela M., Madden, Stephen F., Morgan, Clare, Kalachand, Roshni, McAlpine, Jessica N., Toomey, Sinead, Huntsman, David G., Grogan, Liam, Breathnach, Oscar, Morris, Patrick, Carey, Mark S., Scott, Clare L., Hennessy, Bryan T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345958/ https://www.ncbi.nlm.nih.gov/pubmed/35501389 http://dx.doi.org/10.1038/s41416-022-01823-5

Ejemplares similares

Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
por: Lee, Cha Len, et al.
Publicado: (2023)

Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
por: Kalachand, Roshni D., et al.
Publicado: (2020)

Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium
por: Dharmapatni, Anak ASSK, et al.
Publicado: (2009)

Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples
por: Toomey, Sinead, et al.
Publicado: (2020)

Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
por: Mezynski, M. Janusz, et al.
Publicado: (2021)

A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib
por: O’Shea, John, et al.
Publicado: (2017)

Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation
por: Gill, Catherine, et al.
Publicado: (2009)

Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression
por: Paschall, Amy V, et al.
Publicado: (2014)

Prognostic value of inhibitors of apoptosis proteins (IAPs) and caspases in prostate cancer: caspase-3 forms and XIAP predict biochemical progression after radical prostatectomy
por: Rodríguez-Berriguete, Gonzalo, et al.
Publicado: (2015)

Regulation of Apoptosis by Inhibitors of Apoptosis (IAPs)
por: Berthelet, Jean, et al.
Publicado: (2013)

MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition
por: Ding, X, et al.
Publicado: (2009)

IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis
por: Perimenis, Philippos, et al.
Publicado: (2016)

Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs
por: Verhagen, Anne M, et al.
Publicado: (2001)

The Inhibitor of Apoptosis (IAPs) in Adaptive Response to Cellular Stress
por: Marivin, Arthur, et al.
Publicado: (2012)

XIAP and cIAP1 amplifications induce Beclin 1-dependent autophagy through NFκB activation
por: Lin, Fang, et al.
Publicado: (2015)

ZFP36 stabilizes RIP1 via degradation of XIAP and cIAP2 thereby promoting ripoptosome assembly
por: Selmi, Tommaso, et al.
Publicado: (2015)

Combination of quercetin and cisplatin enhances apoptosis in OSCC cells by downregulating xIAP through the NF-κB pathway
por: Li, Xin, et al.
Publicado: (2019)

Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development
por: Madden, Stephen F., et al.
Publicado: (2022)

A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer
por: Moon, Jai-Hee, et al.
Publicado: (2015)

Potent and Selective Small-Molecule Inhibitors of cIAP1/2 Proteins Reveal That the Binding of Smac Mimetics to XIAP BIR3 Is Not Required for Their Effective Induction of Cell Death in Tumor Cells
por: Sun, Haiying, et al.
Publicado: (2014)

IAP inhibitors enhance co-stimulation to promote tumor immunity
por: Dougan, Michael, et al.
Publicado: (2010)

Inhibitor of Apoptosis (IAP) proteins as drug targets for the treatment of cancer
por: Vaux, David L
Publicado: (2009)

IAPs on the move: role of inhibitors of apoptosis proteins in cell migration
por: Oberoi-Khanuja, T K, et al.
Publicado: (2013)

Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro
por: Aslan, Ozlem, et al.
Publicado: (2018)

Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers
por: Milewska, Malgorzata, et al.
Publicado: (2018)

The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization
por: Kluger, Harriet M, et al.
Publicado: (2007)

Poly(I:C) induces intense expression of c-IAP2 and cooperates with an IAP inhibitor in induction of apoptosis in cancer cells
por: Friboulet, Luc, et al.
Publicado: (2010)

A Giant Ubiquitin-conjugating Enzyme Related to IAP Apoptosis Inhibitors
por: Hauser, Hans-Peter, et al.
Publicado: (1998)

Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma
por: Augello, Claudia, et al.
Publicado: (2009)

Probing SH2-domains using Inhibitor Affinity Purification (IAP)
por: Höfener, Michael, et al.
Publicado: (2014)

Inhibitor of Apoptosis Proteins (IAPs) as therapeutic targets in Multiple Myeloma (MM)
por: Ramakrishnan, Vijay, et al.
Publicado: (2014)

Targeting the BIR Domains of Inhibitor of Apoptosis (IAP) Proteins in Cancer Treatment
por: Cossu, Federica, et al.
Publicado: (2019)

Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)
por: Rathore, Rama, et al.
Publicado: (2017)

IAP inhibitor plus chemoradiotherapy for the treatment of bulky anal canal carcinoma
por: De Felice, Francesca, et al.
Publicado: (2023)

The Effect of Xevinapant Combined with Ionizing Radiation on HNSCC and Normal Tissue Cells and the Impact of Xevinapant on Its Targeted Proteins cIAP1 and XIAP
por: Fleischmann, Julia, et al.
Publicado: (2023)

MON-LB77 Inhibitors of XIAP as Novel Therapeutic Agents in Thyroid Cancer
por: Chu, Simon, et al.
Publicado: (2020)

Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system
por: Bound, Nirashaa T., et al.
Publicado: (2022)

TRAF2/3 deficient B cells resist DNA damage-induced apoptosis via NF-κB2/XIAP/cIAP2 axis and IAP antagonist sensitizes mutant lymphomas to chemotherapeutic drugs
por: Vashisht, Monika, et al.
Publicado: (2023)

Comprehensive molecular characterization of inhibitors of apoptosis proteins (IAPs) for therapeutic targeting in cancer
por: Liang, Jianfeng, et al.
Publicado: (2020)

Molecular and Functional Characterization of Inhibitor of Apoptosis Proteins (IAP, BIRP) in Echinococcus granulosus
por: Zhan, Jiafei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_db8cqj8s657qb2r9kh0m60eds0